Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
Long-Acting Amylin Agonist AZD6234 AZD6234 is a novel long-acting selective AMY3R agonist developed by AstraZeneca for SC administration, and is currently in phase 2 testing [114]
For the 500 mcg peptide (5 mg vial): use 2 mL for 2.5 mg/mL, making 500 mcg equal to 20 units
Some key features and benefits of tirzepatide include: Blood sugar control: Tirzepatide helps lower blood sugar levels by stimulating the release of insulin, which helps move glucose into cells for energy, and by reducing the production of glucose in the liver
Although they can be given safely as frequently as once a week, we recommend once every 2 to 4 weeks
Greater insulin sensitization
Both peptides maintain stability across the same pH range (4.0-8.0), so there are no compatibility concerns in the blended format
US$ 27.37
US$ 28.97
US$ 27.92
US$ 28.56
US$ 29.23
US$ 28.22
